Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00666380 · ClinicalTrials.gov registry record · Phase 1

A Study to Determine the Effects of an Investigational Malaria Vaccine Given to Adults Living in the United States and Thereafter to Adults Living in Kenya

A Phase 1 study, sponsored by U.S. Army Medical Research and Development Command.

Completed
Registry status
Phase 1
Development phase
26
Enrollment target

NCT00666380 is a Phase 1 study that has completed, run by U.S. Army Medical Research and Development Command. The registered enrollment target is 26 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00666380, a Phase 1 study, has completed, sponsored by U.S. Army Medical Research and Development Command.

COMPLETED
Registry status
Phase 1
Development phase
26 participants
Enrollment target

Study Summary

The purpose of this study is to determine whether an investigational malaria vaccine is safe and induces an immune response against malaria when tested in adults living in the United States.

Interventions

  • BIOLOGICAL Plasmodium falciparum Malaria Protein 010 (FMP010)

Trial Details

FieldValue
Enrollment Target 26 participants
Start Date 2008-04
Est. Completion 2009-06
Phase Phase 1

What the Registry Record Tells You About NCT00666380

The ClinicalTrials.gov registry entry for NCT00666380 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is U.S. Army Medical Research and Development Command, which has 77 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Plasmodium falciparum Malaria Protein 010 (FMP010) is the first listed.

NCT00666380 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00666380 about?

NCT00666380 is a clinical study titled "A Study to Determine the Effects of an Investigational Malaria Vaccine Given to Adults Living in the United States and Thereafter to Adults Living in Kenya". The purpose of this study is to determine whether an investigational malaria vaccine is safe and induces an immune response against malaria when tested in adults living in the United States.

What is the current status of trial NCT00666380?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 26 participants. The study started on 2008-04. Estimated completion is 2009-06.

What interventions are being tested in trial NCT00666380?

The interventions under investigation include: Plasmodium falciparum Malaria Protein 010 (FMP010) (BIOLOGICAL).

Who is sponsoring clinical trial NCT00666380?

This trial is sponsored by U.S. Army Medical Research and Development Command, which has 77 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.